Lindbrook Capital, LLC
- SEC CIK
- 0001767045
- Latest filing
- May 5, 2025
DNLI holding history
Denali Therapeutics Inc. in every 13F filed by Lindbrook Capital, LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
DNLI overviewAll 13F holders of DNLIFull Q1 2025 holdings
- Shares (Q1 2025)
- 153
- Value
- $2.08K
- % of portfolio
- <0.1%
- Quarters held
- 15
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q1 2025 | 153 | $2.08K | <0.1% | −102−40.0% | Reduced | Holders |
| Q4 2024 | 255 | $5.20K | <0.1% | −28−9.9% | Reduced | Holders |
| Q3 2024 | 283 | $8.24K | <0.1% | +58+25.8% | Added | Holders |
| Q2 2024 | 225 | $5.22K | <0.1% | −89−28.3% | Reduced | Holders |
| Q1 2024 | 314 | $6.44K | <0.1% | −332−51.4% | Reduced | Holders |
| Q4 2023 | 646 | $13.9K | <0.1% | +407+170.3% | Added | Holders |
| Q3 2023 | 239 | $4.93K | <0.1% | −403−62.8% | Reduced | Holders |
| Q2 2023 | 642 | $18.9K | <0.1% | +188+41.4% | Added | Holders |
| Q1 2023 | 454 | $10.5K | <0.1% | +99+27.9% | Added | Holders |
| Q4 2022 | 355 | $9.87K | <0.1% | +78+28.2% | Added | Holders |
| Q3 2022 | 277 | $9.00K | <0.1% | +54+24.2% | Added | Holders |
| Q2 2022 | 223 | $7.00K | <0.1% | +19+9.3% | Added | Holders |
| Q1 2022 | 204 | $7.00K | <0.1% | −407−66.6% | Reduced | Holders |
| Q4 2021 | 611 | $27.0K | <0.1% | +611 | New | Holders |
| Q2 2021 | 0 | $0 | 0.0% | −34−100.0% | Sold out | Holders |
| Q1 2021 | 34 | $2.00K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.